Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

Exclusion Criteria

• •Subjects who underwent IPL treatment less than 6 months prior to screening
• •Concurrent eyelid infection, which to the opinion of the study investigator is not related to the chalazion
• •Chalazion with atypical features, which to the opinion of the study investigator is inadequate for a study
• •Chronic Chalazion
• •Recurring Chalazion
• •Floppy eyelid syndrome
• •Demodex blepharitis patients taking Lotilaner ophthalmic solution within 30 days prior to screening
• •Ocular surgery within 3 months prior to screening
• •Current diagnosis of malignant tumors in the affected eyelid, including: sebaceous carcinoma and basal cell carcinoma
• •Laser Assisted In Situ Keratomileusis (LASIK)/Small Incision Lenticule Extraction (SMILE) surgery, within 1 year prior to screening
• •Radial Keratotomy (RK) surgery
• •Recent ocular trauma, within 3 months prior to screening
• •Pre-cancerous lesions or skin cancer in the planned treatment area
• •Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
• •Uncontrolled infections or uncontrolled immunosuppressive diseases
• •Best corrected visual acuity worse than 20/200 in either eye
• •Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., prior chemical burn, Epithelial Basement Membrane Dystrophy - EBMD)
• •Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
• •Active sun burn in the treatment area
• •Anterior chamber inflammation
• •Corneal edema
• •Any condition revealed whereby the investigator deems the subject inappropriate for this study